Zheng Quan Ri Bao·2026-02-11 13:08Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, is a key contributor to the company's revenue, with innovative drug sales showing a robust growth trajectory and expected to expand further due to new product inclusions in national insurance directories [1] Group 1: Financial Performance - In the first three quarters of 2025, the company's innovative drug revenue exceeded RMB 6.7 billion, representing an 18.09% increase compared to the same period last year [1] - The company is experiencing steady growth in its innovative drug revenue, indicating a positive trend in its financial performance [1] Group 2: Market Expansion - The inclusion of products such as Fumai Ning, Futuoning, Wantile, and Purin in the national medical insurance directory is expected to further expand the market coverage for the company's innovative drugs [1] - The new inclusion of Yikaida in the commercial insurance innovative drug directory is anticipated to provide additional revenue growth opportunities [1] Group 3: Future Growth Drivers - Continuous progress in the clinical development of the company's innovative pipeline is expected to drive revenue growth for innovative drugs in subsequent years [1]